Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2022-02-25 00:00:00 ET · period of report 2022-02-23 · accession 0001209191-22-013118 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-25 | 2022-02-23 | LYEL | Bishop Hans Edgar | Dir | M - OptEx | $0.1 | +993.4K | 4.54M | +28% | +$99.3K |
| D | 2022-02-25 | 2022-02-23 | LYEL | Bishop Hans Edgar | Dir | M - OptEx | $0.00 | -993.4K | 169.6K | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-23 | M | A | 993,428 | $0.1 | 4,540,234 | D | — | — | |
| 2 | Derivative | Option (right to buy) | 2022-02-23 | M | D | 993,428 | $0.00 | 169,610 | D | $0.1 · — to 2028-11-05 | 993,428 Common Stock | (F1) 1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |